ABOUT US

VISION

The world has never been in more need for novel cures of infectious viruses. CytoAgents is decoding the underlying reasons for life-threatening symptoms. CytoAgents is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases including Covid-19. We are taking a radically different approach to solving this health problem: immunotherapy. Immunotherapy has transformed cancer treatment. Our product will exert the same impact on the treatment of viral respiratory diseases including Covid-19 and influenza. Our immunotherapy is easily administered and cost-effective. Our goal: greater global accessibility and saving lives.

 

LEADERSHIP

TERESA WHALEN, RPh  |  Chief Executive Officer


With more than 20 years in the healthcare industry as a biotech innovator, health technology leader, life sciences investor, and clinical pharmacist Teresa has a successful track record of bringing life-changing healthcare products to market.

 

As the CEO of CytoAgents, Teresa leads a team of world-renowned clinical drug development experts and scientific advisory board members who are at the forefront of groundbreaking solutions to combat persistent and potentially deadly strains of Influenza, COVID19 and other viruses. We are building a platform to revolutionize treatment for respiratory illnesses and viral epidemics.

 

We at CytoAgents are proud to be on the front lines in the battle against influenza, COVID19 and other viruses.

JODI CRAIGO, PhD  |  Chief Science Officer

Jodi is a progressive, insightful, and strategic business-minded scientist administrator with over 20 years of experience leading NIH and corporate-funded research programs. Detail-oriented expert in microbial pathogenesis, host-pathogen interactions, microbial immunology, immune system monitoring, and diagnostic development with rigorous project management skills. Strong interpersonal and relationship-building mediator with extensive oral and written communication capacities. Played key roles in securing IP protections, evaluating and negotiating licensing agreements in cooperation with industrial collaborators. Rapidly proficient in new skill acquisition as proven through decades of expansive scientific and professional expertise.

TODD LORENZ, MD  |  Chief Medical Officer


Todd is an experienced clinical development professional with 15 years in upper management positions at Johnson & Johnson, Cor Therapeutics, Orexigen, Catalyst Biosciences and Corgentech. Also, as SVP, Clinical Development and Scientific Licensing at Portola Pharmaceuticals, Todd held primary responsibility for the Phase 3 program of betrixaban, involving 500 sites in 30 countries. Todd is also an advisor to the Stanford SPARK program and holds a BA in Chemistry from Case Western Reserve University and an MD from Case Western Reserve University, School of Medicine.

SARA MCKENZIE, PhD, MBA  |  Program Director

With more than thirty years in the drug development industry serving both small biotechnology and large pharmaceutical companies, Sara is the Program Director for CytoAgents.  As an experienced executive, Sara is skilled at pulling together multidisciplinary teams to achieve a common goal, in complex matrix environments. Sara has led multiple successful INDs and early development programs and performed oversight of CMC activities, including manufacturing process development and manufacturing operations. 

 

WILL FREDERICK, MBA  |  Chief Financial Officer

Will is a senior financial executive with extensive leadership experience and a proven record of developing and implementing strategies to drive revenue growth, increase profitability and achieve corporate objectives. Will has global experience with publicly traded and privately held companies ranging from early stage start-ups to Fortune 100 enterprises. During his career as a C-level executive, Will has successfully completed over $850M in private and public financings and M&A transactions.

 

SCIENTIFIC ADVISORS

Dr. Michael Ison, MD, MS  |  Director, Transplant Infectious Disease Service NorthWestern

Dr. Ison received his BA at Grinnell College in Grinnell, Iowa. He then received his MD at the University of South Florida College of Medicine followed later by an MS in Health Evaluation Sciences at the University of Virginia. He completed his Internal Medicine training at Oregon Health Sciences University in Portland, OR, and Infectious Diseases training at the University of Virginia, and an additional year of Transplant Infectious Diseases training at the Massachusetts General Hospital. Specialties: Transplant and Immunocompromised Host Infectious Diseases.

 

Dr. Paul Thomas, PhD  |  St. Jude Children’s Research Hospital

Dr. Thomas received his PhD, Immunology and Infectious Disease from the Harvard T.H. Chan School of Public Health.  Paul’s research program is focused on understanding how innate and adaptive immunity determine disease outcomes following influenza virus infection in murine and human experimental systems. Through his work immune signatures predictive of severe disease and poor clinical outcome in patients infected with influenza virus have been identified. Paul’s lab is part of the Center for Excellence for Influenza Research and Surveillance at St. Jude.

 

Dr. Albert Osterhaus, PhD  |  Scientific Director at Viroclinics Biosciences BV | Amsterdam, Netherlands

As a veterinarian with a PhD in Virology from Utrecht University, Ab Osterhaus became head of the Department of Immunobiology at RIVM in The Netherlands. As professor of Virology at Utrecht University and professor and head of the Virology Department of Erasmus Medical Centre, Rotterdam, he developed a long track record as PI of numerous international scientific projects, guiding a multidisciplinary team of over 100 “Viroscience” colleagues studying human and animal virus infections. More than 50 human and animal viruses were discovered (e.g. human metapneumovirus, SARS-CoV, MERS-CoV, several influenza viruses), their pathogenesis elucidated, and intervention strategies developed. He helped national and international health authorities like WHO, to combat emerging human infections like SARS, MERS, H5N1 and H7N7 avian influenza. He established several spin-out companies. Currently he is Professor and Founding Director of RIZ at the University of Veterinary Medicine Hannover and Chair of the European Working Group on Influenza (ESWI) and of the International One Health Platform (OHP). He organized numerous international scientific conferences, holds several senior editorships, published >1200 papers (H-index >100), trained >80 PhD’s, received numerous prestigious awards, is member of the Dutch and German National Academies of Sciences, and Commander of the Order of the Dutch Lion

 

BOARD

Teresa Whalen, RPh  |  Chief Executive Officer and President

 

Catherine V. Mott  |  Founder, CEO, Managing Partner Blue Tree Capital Group

Catherine is the founder and CEO of BlueTree Capital Group and BlueTree Allied Angels.  Catherine is the past Chairman of the Angel Capital Education Foundation, Chairman of the Board of the Angel Capital Association, on the SEC Advisory Committee on Small and Emerging Companies.

 

Catherine had founded Synergetic Sales Performance Group, and Indigo Capital Development, LLC.  In 2002, she was recognized as one of Pennsylvania’s 50 Best Women in Business.  Previously, Catherine worked 17 years in corporate banking management where she served in senior management roles. 

Anthony McCarley  |  CEO, Business Coach, Executive Coach, Keynote Speaker

Anthony is founder of McCarley International which has a mission of guiding business owners, executives, and organizations who are driven to truly accomplish great things. McCarley International specializes in working with companies experiencing significant change and transition – whether by design or circumstance.  Anthony has over 30 years of experience as a senior executive with two Global 100 companies and two start-up companies. Anthony walks the walk and talks the talk.

Anthony became a Triple Crown marathon swimmer in 2014 by crossing the English Channel, circumnavigating Manhattan Island, and crossing the Catalina Channel in southern California. He completed the three marathon swims in less than one year. He was named a 2014 Global Marathon Swimming Federation Award finalist in the Most Impressive Overall Year category.

© 2020 by CytoAgents

  • LI-In-Bug